TD Cowen on Olema Pharmaceuticals (OLMA): 'Pala's Profile And Data Support Phase IIIs, Despite persevERA Disappointment'
Tweet Send to a Friend
TD Cowen analyst Tyler Van Buren reiterated a Buy rating on Olema Pharmaceuticals (NASDAQ: OLMA).The analyst comments "The failure of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
